# OnCo record paper-nifty-liposomal-irinotecan-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nifty-liposomal-irinotecan-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nifty-liposomal-irinotecan-lancet-oncol-2021" ;
  schema:name "Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study"@en ;
  schema:description "In a Korean trial, adding liposomal irinotecan to fluorouracil held second-line bile duct and gallbladder cancer still for about seven months rather than six weeks, at the cost of more low blood counts."@en ;
  schema:url <https://onco.cc/key-papers/paper-nifty-liposomal-irinotecan-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(21)00486-1>, <https://pubmed.ncbi.nlm.nih.gov/34656226/>, <https://clinicaltrials.gov/study/NCT03524508> ;
  onco:tag "gallbladder-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(21)00486-1> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Yoo C, Kim KP, Jeong JH, et al." ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:drugs <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/fluorouracil/> ;
  onco:terms <https://onco.cc/terms/pfs/> ;
  onco:trials <https://onco.cc/trials/nifty/>, <https://onco.cc/trials/naliricc/> ;
  onco:people <https://onco.cc/people/ghassan-abou-alfa/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .